You can buy Lucialpe at the lowest price at Nextgen.ooo online pharmacy. Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It acts by selectively inhibiting PI3K p110α 2 class I, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in a variety of biological processes including proliferation, survival, differentiation, and metabolism.
 
Alpelisib was designed to target this enzyme, which appears to be mutated in nearly 30% of human cancers, leading to hyperactivation. Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with fulvestrant in postmenopausal women and male patients. Initiation of alpelisib requires confirmation of the PIK3CA mutation in tissue and/or liquid biopsy samples using diagnostic tests.
 
Studies evaluating the therapeutic efficacy of alpelisib in other cancers, such as ovarian cancer and colorectal cancer, are under investigation.
In April 2022, the FDA approved alpelisib for the treatment of PIK3CA-associated overgrowth spectrum (PROS) in adults and children who require systemic therapy.